Anticoagulation in COVID-19: reaction to the ACTION trial. | Lancet;397(10291): 2226-2228, 2021 06 12. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

WHO COVID-19 Research Database

News/Update/Help

Advanced Search

The WHO Covid-19 Research Database is a resource created in response to the Public Health Emergency of International Concern (PHEIC). Its content remains searchable and spans the time period March 2020 to June 2023. Since June 2023, manual updates to the database have been discontinued.

Anticoagulation in COVID-19: reaction to the ACTION trial.

Berger, Jeffrey S; Connors, Jean Marie.

Berger JS; Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, NY 10016, USA; New York University Langone Health, New York, NY, USA. Electronic address: jeffrey.berger@nyulangone.org.
Connors JM; Brigham and Women's Hospital, Boston, MA, USA.

Lancet ; 397(10291): 2226-2228, 2021 06 12.

Article in English | MEDLINE | ID: covidwho-1263398

Subject(s)

COVID-19; Anticoagulants/adverse effects; Fibrin Fibrinogen Degradation Products; Hospitals; Humans; SARS-CoV-2

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Randomized controlled trials Limits: Humans Language: English Journal: Lancet Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Randomized controlled trials Limits: Humans Language: English Journal: Lancet Year: 2021 Document Type: Article